What to know about immunotherapy — innovative treatment doc used on his own cancer nypost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nypost.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin.
Jeffrey S. Weber, MD, PhD, highlighted key efficacy findings from the mRNA-4157-P201/KEYNOTE-942 trial, expanded on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma, and underscored the importance of continued research on mRNA vaccines paired with standard PD-1 therapy across cancer types.